Interestingly, melanoma cells are reported to secrete sEVs carrying a high level of PD‐L1 and effectively suppress CD8+ T cell activity.[11] Thus, combinational inhibition of both PD‐1 and other ICPs on T cells by using sEVs simultaneously carrying multiple target ligands might be a more potent therapeutic strategy for attenuating T‐cell mediated immune rejections. The gene discussed is CD8A; the disease is melanoma.